Go Back

Biodesix’ Paul Beresford Joins 2012 BIO Panel for Personalized Medicine Commercialization

Line Up Includes Beresford, Industry Veterans from Roche, AstraZeneca and Life Technologies

Biodesix, Inc., a fully integrated molecular diagnostics company dedicated to personalizing medicine, today announced that Paul Beresford, Ph.D., Vice President of Business Development and Strategic Marketing, will join industry veterans on a panel discussing the recipe for the successful commercialization of personalized medicine at the 2012 BIO International Conference being held in Boston, Mass. June 18-21, 2012.

The panel, “Commercialization of Personalized Medicine: Stakeholders’ Recipe For Success,” will take place on Tuesday, June 19th from 3:45-5:00 p.m. EST. Beresford joins Mara Aspinall, president and CEO of Ventana Medical Systems, a Roche Group; Glenn Miller, Vice President and Head of Personalized Medicine at AstraZeneca; and Ron Andrews, President, Medical Sciences at Life Technologies on the panel. With help from the panelists, who are successfully pioneering diagnostic products for personalized medicine, this session will gauge the power of collaboration to fuel personalized medicine and novel diagnostics, detail early successes, identify major challenges and debate the most attractive models for commercialization. The panel will be moderated by Kristin Pothier, Partner at Health Advances LLC, a healthcare strategy firm specializing in strategic guidance for all apsects of medical technology commercialization.

“As personalized therapies continue to see rapid growth from the research side, this is the ideal time to create new business models that optimize the delivery of personalized medicine to patients by providing appropriate incentives to the businesses developing and commercializing these products ,” said Beresford. “I am honored to join this group of innovators in discussing how to best approach this challenge”

Biodesix developed, validated and commercialized VeriStrat®, a serum proteomic test currently available  to help physicians guide treatment decisions for patients with advanced non-small cell lung cancer. The test identifies patients who are likely to have good or poor outcomes after treatment with epidermal growth factor receptor inhibitors (EGFRIs) using a simple blood draw. VeriStrat is based on ProTS®, proprietary technology which harnesses the power of mass spectrometry and enables the discovery of specific molecular profiles that characterize a patient’s condition or likely outcome in response to therapy. Biodesix collaborates with clinical investigators and also partners with biotechnology and pharmaceutical companies to develop diagnostics that can determine which patients are most likely to benefit from novel therapies.

About Biodesix: Biodesix is a personalized medicine company focused on the development of diagnostic products that inform treatment decisions and improve patient care.  The Company’s goal is to give physicians more information about the patient and their disease; understanding the clinically meaningful information contained within each patient’s molecular profile leads to better care and better outcomes. The Company’s unique approach is based on ProTS®, proprietary technology which harnesses the power of mass spectrometry and enables the discovery of specific molecular profiles. Biodesix collaborates with clinical investigators to address critical clinical questions, and partners with biotechnology and pharmaceutical companies to develop diagnostics to select patients most likely to benefit from novel therapies. For more information about Biodesix, please visit www.Biodesix.com.


Kena Hudson or Rachel Lear

Chempetitive Group for Biodesix



For Customer Support, call: (866) 432-5930

Topics: blood-based cancer test, Business Development, cancer diagnostics, Commercialization of Personalized Medicine: Stakeh, EGFRIs, personalized medicine, Press Releases, proteomic test, ProTS, serum proteomic test, Strategic Marketing, Veristrat, liquid biopsy, lung cancer, molecular diagnostic, Non-Small Cell Lung Cancer, NSCLC, oncology